ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
50 announcements
Q2FY27 operating revenue ₹230.23 Cr, operating EBITDA ₹42.33 Cr (18.02% margin), PAT ₹31.03 Cr (13.21%) after API exit; now net debt-free FDF pure-play.
Ind-Swift Laboratories Limited submitted its quarterly monitoring agency report for the period ended September 30, 2026. The report covers the utilization of Rs. 137.20 Crore raised via warrants.
Ind-Swift Laboratories has fully utilized the Rs. 314.60 Crore proceeds from its preferential issue of convertible warrants. The monitoring agency CARE Ratings confirms no deviations in fund usage.
Ind-Swift Laboratories reported Q2 FY27 revenue up 50% to ₹234.89 crore and PAT up 3.5x to ₹31.03 crore. Operating EBITDA margin rose to 18.02%.
Ind-Swift Laboratories Ltd reported revenue from operations of ₹240.5 Cr (+51.6% YoY) and net profit of ₹34.2 Cr (+327.5% YoY) for Q2 FY27.
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.
Essix Biosciences Limited acquired 14,00,000 equity shares of Ind-Swift Laboratories Limited following the conversion of fully convertible warrants. The company disclosed this under SEBI regulations.
Ind-Swift Laboratories allotted 14,00,000 equity shares upon conversion of warrants at Rs. 196 each. The allotment follows a previously approved preferential issue.
Ind-Swift Laboratories allotted 14 lakh equity shares upon converting warrants for Essix Biosciences Limited, receiving ₹20.58 Crore. This increases the company's paid-up equity share capital.
Ind-Swift Laboratories Limited held its 31st Annual General Meeting on September 30, 2026. Members approved audited financial statements and director appointments.
KMP Pardeep Verma sold 6,140 equity shares of Ind-Swift Laboratories Ltd via market sale, reducing his holding by 0.01%.
Ind-Swift Laboratories Ltd has filed its quarterly shareholding pattern as mandated by Regulation 31(1)(c) of the SEBI Listing Regulations.
Promoter entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants of Ind-Swift Laboratories via a preferential allotment.
Ind-Swift Laboratories allotted 70 lakh fully convertible warrants at Rs. 196 each, totaling Rs. 137.2 Crore. This preferential issue will augment capital upon warrant conversion.
Ind-Swift Laboratories Limited allotted 70,00,000 fully convertible warrants to Essix Biosciences Limited on a preferential basis. The company received Rs. 34.30 Crore as upfront payment.
Ind-Swift Laboratories has submitted its Annual Report for the financial year 2025-26. This filing provides the company's detailed financial performance and operational updates.
Ind-Swift Laboratories Ltd will hold its 31st Annual General Meeting on September 30, 2026, via video conference. The agenda includes financial adoption and director appointments.
Ind-Swift Laboratories' Preferential Issue Committee approved a revised issue price of Rs. 196 per warrant. The pricing follows SEBI ICDR regulations and a revised valuation report.
Ind-Swift Laboratories Limited appointed Mr. Amit Mathur as a Non-Executive Independent Director, effective September 3, 2026. He brings over three decades of banking and financial expertise.
Ind-Swift Laboratories appointed Mr. Amit Mathur as an Independent Director and scheduled its 31st AGM for September 30, 2026.
Ind-Swift Laboratories clarified that the recent increase in share trading volume is purely market-driven. The company confirmed it has disclosed all material information as required.
Ind-Swift Laboratories will invest Rs. 45 crore to upgrade its Jammu facility to EU-GMP standards. This expansion targets additional annual revenue of Rs. 100 crore by 2029-30.
ISLL is transitioning from an API player to a pure-play Finished Dosage Formulation (FDF) manufacturer. Post-API business divestment, company is net debt-free with significant growth in EBITDA margins.
Ind-Swift Laboratories reported Q1 FY27 results with operating income of ₹186.08 Crore. PAT (excluding exceptional items) grew 2.04x YoY to ₹24.68 Crore.
Ind-Swift Laboratories Limited submitted a nil statement of deviation or variation for funds raised through its preferential issue of convertible warrants for the quarter ended June 30, 2026.
Ind-Swift Laboratories Ltd reported revenue from operations of ₹191.5 Cr (+21.0% YoY) and net profit of ₹24.7 Cr (+180.7% YoY) for Q1 FY27.
Ind-Swift Laboratories disclosed voting results of its EGM held on August 5, 2026, where resolutions including warrant issuance were approved by shareholders.
Ind-Swift Laboratories Ltd has scheduled a board meeting on August 10, 2026, to consider and approve its standalone and consolidated financial results for the quarter.
Ind-Swift Laboratories issued a corrigendum to its EGM notice regarding a preferential issue of 70,00,000 warrants, detailing the utilization of Rs. 137.20 Crore in proceeds.
Ind-Swift Laboratories issued a corrigendum to its EGM notice for the proposed preferential issue of fully convertible warrants, following queries from stock exchanges.